Treatments targeting TLR7/8 and TLR9 are in Phase I trials in patients with SLE and should provide insight into the role of TLR signaling in lupus including whether these therapies will be more effective in women than men [19]–[22]. Here, TLR7 is linked to systemic lupus erythematosus.